Kalyan is the Founder and Chief Executive of Inference Inc. With over 25+ years of experience in clinical biostatistics managing all phases of drug development, he brings a wealth of experience from his years in both big pharma and CROs. He has spent 13 years at Merck (in both early & late phases) and 4 years at BMS (late phase). He has led multiple regulatory filings for drugs and biologics with agencies world-wide. He also founded Vislation, a boutique CRO supported by Merck Capital Ventures, and which is now part of Cytel.

Kalyan serves as an expert statistical reviewer for several journals including The Lancet. Kalyan is a Fellow of the American Statistical Association.